Medical/Pharmaceuticals News & Press Release Distribution

Medical/Pharmaceuticals

APAC
Global

HaemaLogiX strengthens Board with appointment of Dr. Geoff Nichol

* Dr. Geoff Nichol, M.B., Ch.B., M.B.A., joins HaemaLogiX's Board of Directors as Non-Executive Director, bringing nearly 30 years of global drug development experience * Past achievements include approval of Augmentin BID for adults and children, plus foundational clinical development of bre...

2022-07-08 05:30 3647

Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine

* Insilico and its collaborators scoured massive datasets and found genes relevant to ALS through PandaOmics™, Insilico's proprietary AI-driven target identification engine. * 28 targets were identified from CNS and diMN samples; for 18 targets (64%), suppression moderately or strongly rescue...

2022-07-08 04:00 4124

United Imaging To Feature Leaders of Choice Program, Innovative Purchasing Models, and World's-First Equipment at AHRA in Phoenix

Leaders of Choice is the educational program United Imaging and AHRA Announced Jointly in May. HOUSTON, July 7, 2022 /PRNewswire/ -- United Imaging confirmed that its Houston-based U.S. leadership team will be on hand in Phoenix for the AHRA (Association for Medical Imaging Management) Annual Me...

2022-07-07 20:18 2465

SunHo Announces First Patient Dosed in Phase 1/2 Clinical Trial of Two First-in-class Immunocytokines: IAP0971 and IAE0972

NANJING, China, July 7, 2022 /PRNewswire/ -- SunHo BioPharmaceutical Co., Ltd. ("SunHo"), a clinical-stage leading biopharma in immunocytokines with full-set of capabilities from discovery to commercialization, announced that IAP0971 (PD1-IL15 immunocytokine) and IAE0972 (EGFR-IL10 immunocytokine...

2022-07-07 20:00 2355

Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines

GUANGZHOU, China, July 7, 2022 /PRNewswire/ -- Recently, Zhiyi Biotech announced that it has raised$15 million in its B++ funding round. The funds will be used to boost the clinical development of the company's live biotherapeutic products (LBPs) pipelines. It's worth mentioning thatZhiyi has su...

2022-07-07 17:45 1939

ASUS and Tan Tock Seng Hospital co-develop an AI-based tool to improve the accuracy and efficiency of diagnosis in blood diseases

Both parties inked an MOU to accelerate integration of AI-powered solutions into clinical care, to supportSingapore's healthcare transformation SINGAPORE, July 7, 2022 /PRNewswire/ -- ASUS and Tan Tock Seng Hospital (TTSH) inked a three-year Memorandum of Understanding (MOU) earlier today to for...

2022-07-07 16:05 4371

ASUS and Tan Tock Seng Hospital co-develop an AI-based tool to improve the accuracy and efficiency of diagnosis in blood diseases

WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

Site Enhances New Modality CRDMO Platform Capacity for Customers SHANGHAI , July 6, 2022 /PRNewswire/ -- WuXi STA, a subsidiary of WuXi AppTec, today announced the opening of a new large-scale oligonucleotide and peptide manufacturing facility at itsChangzhou campus. The new facility underscores...

2022-07-07 08:00 4916

WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

Brii Biosciences Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

The Company is working closely with its commercial partners to supply the combination therapy to patients in need Brii Bio progressed the combination therapy from discovery to global Phase 3 data readout and first regulatory approval by the China NMPA in less than 20 months, validating the Com...

2022-07-07 07:10 5496

SHARE: RESTORING MENTAL HEALTH IN THE NEW NORMAL

SINGAPORE, July 7, 2022 /PRNewswire/ -- TheShareCo announces the launch ofShare, a Singapore-based mental health app that allows students, parents and working adults to seek online therapy in an affordable, accessible and anonymous manner. It is believed to be the fi...

2022-07-07 07:07 3068

Global Cord Blood Corporation Obtained Injunction Order Against Blue Ocean in respect of Purported EGM

HONG KONG, July 7, 2022 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO, "GCBC" or the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that an injunction order (the "Order"...

2022-07-07 04:16 4847

Alterity Therapeutics Doses First Patient in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, July 6, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first patient has bee...

2022-07-06 23:00 3216

I-Mab to Host 2022 R&D Day

GAITHERSBURG, MD. and SHANGHAI, July 6, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it will host its 2022 Research and Devel...

2022-07-06 20:00 2346

US FDA AWARDS RARE PEDIATRIC DISEASE DESIGNATION (RPDD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER

SYDNEY, July 6, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Rare Pediatric Disease Designation (RPDD) to Kazia's paxalisib for t...

2022-07-06 19:00 4193

Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China

Collaboration will provide biopharmaceutical companies access to Guardant Health's broad portfolio of cancer tests to help advance drug development programs and their clinical trials SINGAPORE, July 6, 2022 /PRNewswire/ -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company,...

2022-07-06 18:17 5742

Vieworks to Highlight Its X-ray Flat Panel Detectors Lineup at ECR 2022

ANYANG, South Korea, July 6, 2022 /PRNewswire/ -- Vieworks, a global digital X-ray imaging solution provider based inSouth Korea, is showcasing its 3rd generation DR detectors and its latest dynamic detectors at ECR 2022 (Expo3 #322) fromJuly 13th to 17th.

2022-07-06 15:00 2624

Vieworks to Highlight Its X-ray Flat Panel Detectors Lineup at ECR 2022

Farrer Park Hospital Underscores Commitment to Sustainability with Ongoing Green Initiatives

SINGAPORE, July 6, 2022 /PRNewswire/ -- Sustainability efforts were already embedded in Farrer Park Hospital's ("FPH" or "the Hospital") DNA since its early phase of conceptualisation. Since FPH went operational in 2014, the Hospital has attained optimal energy savings of 30 per cent annually....

2022-07-06 14:00 4341

Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007

SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene ") and HUTCHMED (China) Limited ("HUTCHMED ") (Nasdaq/AIM:HCM; HKEX:13) announces today that the first participant, based inAustralia, was ...

2022-07-06 12:00 2444

harrison.ai and Sonic Healthcare join forces to launch 'franklin.ai', bringing Artificial Intelligence (AI) to pathology

franklin.ai aims to apply the latest methodologies in artificial intelligence (AI) to putgroundbreaking AI tools into the hands of pathologists. SYDNEY, July 6, 2022 /PRNewswire/ -- harrison.ai , the clinically led healthcare AI platform andSonic

2022-07-06 09:58 10471

Esco Lifesciences Group Strengthens IVF Portfolio by Acquiring Evidence Solution

SINGAPORE, July 6, 2022 /PRNewswire/ -- Esco Lifesciences Group ("Esco", the "Company") announces the full acquisition of Evidence Solution ("Evidence"), a Danish software company offering In Vitro Fertilization (IVF) management technologies and quality management systems ("Evidence witness syste...

2022-07-06 09:00 2558

Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19

-- ASC10 is an oral small molecule drug candidate, which is in-house discovered and developed, and Ascletis retains full global rights for its development and commercialization --This IND filing of ASC10 in the U.S. will accelerate Ascletis' global multi-center clinical studies on ASC10 and bett...

2022-07-06 08:10 5131

1 ... 544 545 546547548 549 550 ... 645